- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 20.10. | Infertility treatment heads first drugs on FDA's new priority review scheme | ||
| 20.10. | FDA greenlight for Roche's Alzheimer's disease test sparks care paradigm shift | ||
| 20.10. | ESMO 2025: Eli Lilly's Verzenio extends survival in high-risk early breast cancer | ||
| 17.10. | Market dynamics for generics must change amid ANDA pilot debut | ||
| 17.10. | Adcytherix gains $122m to propel ADC development | ||
| 17.10. | EMD Serono partners US government to widen IVF access | ||
| 16.10. | AstraZeneca doubles Lokelma output with $445m Texas plant expansion | ||
| 16.10. | Novo Nordisk snaps up Omeros' rare disease asset for up to $2.1bn | ||
| 16.10. | Bavarian Nordic's shareholders and board in standoff amid takeover offer | ||
| 16.10. | Tubulis closes $361m in Series C to advance cancer treatment | ||
| 16.10. | Oceanpine Capital to acquire 80% equity stake in Beijing Jacoray | ||
| 15.10. | Healthcare burden of neurological conditions "growing", WHO warns | ||
| 15.10. | Kirkland & Ellis dominates M&A legal advisory in first three quarters of 2025 | ||
| 15.10. | Goldman Sachs and Houlihan Lokey lead in M&A advisory for Q1-Q3 2025 | ||
| 15.10. | Pfizer touts Tukysa in front-line breast cancer after Phase III victory | ||
| 15.10. | Nabla Bio expands Takeda collab for protein therapeutics | ||
| 15.10. | BioCryst to buy Astria Therapeutics for $700m in enterprise value | ||
| 14.10. | J&J spins off orthopaedics business against positive Q3 backdrop | ||
| 14.10. | Kailera nets $600m to power Phase III launch of obesity drug | ||
| 14.10. | China's drugs offer lifeline for global pharma as it peers over the patent cliff | ||
| 14.10. | FDA approves AbbVie's Rinvoq for inflammatory bowel disease | ||
| 14.10. | CIPO grants patent to Palisade Bio's PALI-2108 | ||
| 13.10. | BIOSECURE returns to US pharma agenda with 2.0 update | ||
| 13.10. | AstraZeneca inks Trump drug pricing deal amid tariff threats | ||
| 13.10. | J&J in talks to acquire Protagonist Therapeutics |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .